William Blair Cuts Earnings Estimates for Janux Therapeutics

Janux Therapeutics, Inc. (NASDAQ:JANX) – Equities researchers at William Blair lowered their FY2024 earnings per share estimates for Janux Therapeutics in a research report issued on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will earn ($1.28) per share for the year, down from their previous forecast of ($0.94). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.29) per share. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

A number of other equities research analysts have also recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Scotiabank lowered their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. UBS Group initiated coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $63.00 price objective on shares of Janux Therapeutics in a report on Thursday, November 7th. Finally, Stifel Nicolaus started coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $66.44.

Janux Therapeutics Trading Down 0.4 %

Shares of Janux Therapeutics stock opened at $53.68 on Monday. Janux Therapeutics has a 1-year low of $5.80 and a 1-year high of $65.60. The firm’s 50-day moving average price is $49.16 and its two-hundred day moving average price is $46.40. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -45.88 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The company’s quarterly revenue was down 82.6% on a year-over-year basis.

Insider Buying and Selling

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now directly owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the stock in a transaction dated Friday, October 18th. The stock was bought at an average cost of $44.75 per share, with a total value of $53,700,000.00. Following the purchase, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the transaction, the insider now directly owns 3,162,851 shares in the company, valued at $132,839,742. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 420,610 shares of company stock valued at $19,288,666 over the last ninety days. Insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Large investors have recently bought and sold shares of the company. Logos Global Management LP boosted its position in shares of Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in Janux Therapeutics during the first quarter worth about $20,420,000. Vanguard Group Inc. grew its stake in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the period. Altitude Crest Partners Inc. bought a new stake in shares of Janux Therapeutics in the first quarter worth about $7,278,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Janux Therapeutics during the second quarter worth about $5,715,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.